Secondary Immunodeficiencies and Infections in patients with hematologic malignancies treated with anti-CD20-antibodies

• Conditions: B-cell lymphomas; C82; C83.0; C83.1; C83.3; C83.5; C83.7; C85.1; C91.1; C91.4

• Registration Number: DRKS00023404
• Lead Sponsor: Institut für Versorgungsforschung in der Onkologie GbR

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Diagnosis of a B-cell lymphoma in need of therapy. Planned 1st line therapy with an anti-CD20 antibody (rituximab, obinutuzumab, ofatumumab). Age = 18 years, signed informed consent, sufficient knowledge of German language

Exclusion Criteria

Antibody therapy started before inclusion

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency and severity of infections. This parameter is measured with the help of a patient diary. After the start of therapy, a monthly status of infections is captured over a period of 12 months.

Secondary Outcome Measures

Name	Time	Method
Frequency of IgG deficiencies? Therapy of infections? Frequency of immunoglobulin substitutions? IgG substitution corresponding to guidelines?